


NASDAQ: POCI

Lytham Fall 2025 Investor Conference
September 2025



Forward-Looking Statements

This presentation contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that the Company files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

Non-GAAP Financial Measures

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company has provided the following non-GAAP financial measures in this release and the accompanying tables: adjusted EBITDA. Precision Optics uses this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of its operating performance and liquidity, and believes they are useful to investors as a supplement to GAAP measures in analyzing, trending and benchmarking the performance and value of our business. However, these measures are not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures.

In order to calculate these non-GAAP financial measures, the Company makes targeted adjustments to certain GAAP financial line items found on its Consolidated Statement of Operations, backing out non-recurring or unique items or items that the Company believe otherwise distort the underlying results and trends of the ongoing business. We have excluded the following items from one or more of our non-GAAP financial measures for the periods presented:

Selling, general and administrative expenses; operating expenses. The Company excludes a portion of SG&A expense and operating expenses related to transaction expenses related to acquisitions and financings. Acquisition-related expenses include transaction fees, due diligence costs and other direct costs associated with our acquisitions. These amounts are unrelated to our core performance during any particular period and are impacted by the timing of the acquisition. The Company excludes acquisition-related expenses from the Company's SG&A expense and total operating expenses to provide investors a method to compare our operating results to prior periods and to peer companies, as such amounts can vary significantly based on the frequency of acquisitions and the magnitude of acquisition expenses.

Bad debt expense; operating expenses. The Company excludes a portion of SG&A expense and operating expenses related to bad debt expense. These amounts are unrelated to our core performance during any particular period. The Company believes it is useful to exclude these amounts in order to better understand our business performance and allow investors to compare the Company's results with peer companies.

Adjusted EBITDA is a non-GAAP financial measure that we define as GAAP net income (loss), adjusted to exclude non-recurring transaction costs, bad debt expense, depreciation and amortization, non-cash stock-based compensation, interest expense, and provision (benefit) for income taxes. We believe that the use of adjusted EBITDA is useful to investors and other users of the Company's financial statements in evaluating our operating performance because it provides them with an additional tool to compare business performance across companies and across periods. The Company uses adjusted EBITDA in conjunction with traditional GAAP operating performance measures as part of our overall assessment of our performance, for planning purposes, including the preparation of our annual operating budget, to evaluate the effectiveness of our business strategies and to communicate with our board of directors concerning our financial performance. Management does not place undue reliance on adjusted EBITDA as its only measure of operating performance. Adjusted EBITDA should not be considered as a substitute for other measures of financial performance reported in accordance with GAAP.

Enabling Next Generation Technologies


Precision Optics is a **VERTICALLY INTEGRATED OPTICS COMPANY** primarily focused on leveraging its proprietary **MICRO-OPTICS AND IMAGING TECHNOLOGIES** to the **HEALTHCARE** and **DEFENSE/AEROSPACE** industries by providing services ranging from new product concept through mass manufacture.



Business Model


► Business model driving rapid growth

- Work closely with key medical device and defense companies at the very early design stage of projects, lending the Company's expertise in proprietary micro-optics, 3D imaging, and digital imaging technologies
- Robust pipeline supporting future commercial production opportunities
- Maintain and update IP through internal and customer funded R&D




Revenue Ramp

FY End June




Differentiated Product Technology Offerings



Micro Optics



3D Imaging



Digital Imaging



Key Markets: Medical Device

► MicroPrecision Optics


- Smaller imaging systems enabling next generation minimally invasive surgery

► 3D Endoscopes

- Robotic Surgery

► Digital Imaging

- Full medical device systems
- Single use endoscopes




Red circles indicate current programs in production or development

Key Markets: Aerospace/Defense


- ▶ **SWaP (Size Weight and Power)**

- ▶ **Areas of Focus**

- ▶ Satellite communications
- ▶ UAV/Drones
- ▶ Directed energy weapons



Digital Imaging Systems



Optics

Performance
Size
Fabrication
Assembly
Alignment



Image Sensor

Performance
Size
Interconnect
Mounting
Signal integrity



Illumination

Luminance
Distribution
Power & Thermal
Packaging
Assembly




Video Processing

Quality
Flexibility
Latency
Tuning
Features



Packaging

Sterilization
Biocomp.
Size
Durability
Appearance



System

Product Cost
Quality
Compliance
Project Mgmt.
DFx

Holistic Development

Unity Platform





UNITY PLATFORMS BENEFITS

- Accelerated time to market
 - Reduced development costs
 - De-risk projects
 - Customization gets customers closer to your ideal design parameters
- ▶ Groundbreaking modular optical platform is set to transform the development and production of endoscopic imaging devices by significantly reducing costs, time to market, and project risks
 - ▶ Standard baseline CMOS endoscopic system with customization options based on existing or newly designed sub-components
 - ▶ A Platform Built on a Depth of Experience: Culmination of many years of research, development, and collaboration with key industry players
 - ▶ Revolutionizing the One Customer, One Device Approach: Unity flips this model on its head by delivering a robust, adaptable system that serves as a foundation for entire families of products.

Vertically Integrated Design to Manufacture

Broad Optical Capabilities All Under One Roof



Expanding Product Development Pipeline

Product	Feasibility Study	Prototype Design	Prototype Fabrication	Verification/Validation	Production	Industry	Subsegment	Customer
Multiple Mature "Legacy" Products						Medical Device	Multiple	Multiple
Cystoscope #1						Medical Device	Cystoscopy	Large Medical Device
Optics Components						Defense/Aerospace	Confidential	Top Tier Defense / Aerospace
Cardiovascular Endoscope						Medical Device	Cardiac	CardioFocus
Otoscopy Device #1						Medical Device	Otoscopy	Large Medical Device
Micro Optics Components						Defense/Aerospace	Confidential	Top Tier Defense/Aerospace
Laparoscope						Medical Device	Robotic Laparoscopy	Well-funded Startup
Micro Endoscope						Medical Device	Ophthalmology	Mid-Tier Medical Device
Ophthalmoscope #1						Medical Device	Ophthalmology	Large Medical Device
Arthroscope #1						Medical Device	Arthroscopy	Mid-Tier Medical Device
ENT Scope						Medical Device	Ear, Nose and Throat	Well-funded Startup
Otoscopy Device #2						Medical Device	Otoscopy	Well-funded Startup
Ureteroscope						Medical Device	Urology	Mid-tier Medical Device
Borescope						Industrial	Borescope	Mid-tier Industrial
Laparoscope						Medical Device	Laparoscopy	Large Medical Device
Cystoscope #2						Medical Device	Cystoscopy	Well-funded Startup
Borescope #2						Defense/Aerospace	Aerospace Borescope	Large Defense/Aerospace

Recent Large Orders

► Single-Use Cystoscopy Program

Program leverages POC's technology to supply single-use endoscope assemblies used in a cystoscopy surgery system

- \$9 million production order announced in May 2024
- Production deliveries began in mid-2024
- Company estimates the following delivery schedule:
 - \$2.6 million in fiscal 2025
 - \$4.6 million in fiscal 2026
 - Remainder in the first half of fiscal 2027.

► Top Tier Aerospace Program


Program leverages POC's proprietary manufacturing technology developed for high precision micro-optics systems

- Initially commenced production in September 2023.
- Follow-on orders have been received on an ongoing basis since that time.
- Signed Main Purchase Agreement in April 2025
 - Minimum purchase commitments of nearly \$4 million per year through calendar 2026.
- Current customer program backlog of \$8.9 million expected to be delivered over next 12 months (as of September 2025)

Go Forward Strategy

- ▶ Continue and expand production lines for record backlog especially for two recent large programs
- ▶ Advance pipeline projects to commercialization
- ▶ Expand pipeline with new development programs leveraging recently launched Unity Platform
- ▶ Maintain competitive advantages in micro-optics, 3D imaging and digital imaging
- ▶ Disciplined investment strategy in sales and marketing, as well as engineering capabilities
- ▶ Expand and update facilities to support corporate growth
- ▶ Look for strategic acquisitions to broaden the Company's existing capabilities


FINANCIALS




Financial Snapshot

Annual FY ends June


Revenue



Gross Margins



Adjusted EBITDA



Balance Sheet Highlights

	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Cash and cash equivalents	\$1,134,697	\$861,650	\$605,749	\$2,925,852	\$405,278	\$1,773,735
Accounts receivable, net	\$1,481,437	\$1,878,755	\$2,663,872	\$3,907,407	\$3,545,491	\$4,336,730
Inventory	\$2,197,244	\$1,885,395	\$3,079,938	\$2,776,216	\$2,868,100	\$3,562,112
Total assets	\$6,351,531	\$6,261,300	\$16,704,020	\$19,740,434	\$16,912,574	\$19,790,287
Current Liabilities	\$3,149,380	\$2,511,110	\$4,586,641	\$5,259,620	\$4,906,816	\$6,151,296
Acquisition earn out liability (incl. current portion)	\$500,000	\$333,333	\$872,559	\$0	\$0	\$0
Bank Debt (incl. current portion)	\$0	\$0	\$2,328,855	\$2,689,239	\$2,175,980	\$1,867,103
Total shareholder's equity	\$2,771,761	\$3,431,127	\$8,971,495	\$12,046,592	\$10,067,788	\$12,258,832
Shares Outstanding*	4,397,263	4,427,492	5,638,363	6,066,518	6,073,939	7,714,701

*Reflects 1-for-3 split enacted on November 2, 2022

The background of the slide features a close-up, low-angle shot of two white industrial robotic arms against a deep blue sky. The arms are sleek and modern, with visible joints and sensors. One arm is positioned on the left, and the other is on the right, both pointing towards the center. The lighting is bright, creating a sense of high-tech precision.

THANK YOU

APPENDIX



Income Statement Highlights

	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	Q1	Q2	Q3	Q4	FY 2024	Q1	Q2	Q3	Q4	FY 2025
Revenues	4,038,048	6,804,169	9,923,356	10,674,907	15,678,248	21,044,467	4,321,255	4,824,289	5,242,579	4,716,226	19,104,349	4,197,053	4,526,907	4,185,968	6,181,342	19,091,269
Cost of Goods Sold	2,556,130	4,681,691	6,560,779	7,241,323	10,750,061	13,310,331	2,857,644	3,373,313	3,383,842	3,691,775	13,306,574	3,079,723	3,456,965	3,767,993	5,377,093	15,681,774
Gross Profit	1,481,918	2,122,478	3,362,576	3,433,584	4,928,187	7,734,136	1,463,611	1,450,976	1,858,737	1,024,451	5,797,775	1,117,330	1,069,942	417,975	804,249	3,409,495
Operating Expenses	1,830,537	2,735,021	4,785,559	4,339,158	6,442,078	8,372,684	1,868,904	2,155,138	2,117,264	2,380,803	8,522,109	2,364,271	1,979,963	2,456,260	2,010,842	8,811,337
Operating Income (Loss)	(348,619)	(612,543)	(1,422,983)	(905,574)	(1,513,891)	(638,548)	(405,293)	(704,162)	(258,527)	(1,356,352)	(2,724,334)	(1,246,941)	(910,021)	(2,038,285)	(1,206,593)	(5,401,842)
Other - Interest Expense	(1,859)	(1,416)	(1,001)	(5,302)	(159,538)	(218,927)	(59,122)	(54,640)	(58,528)	(52,818)	(225,108)	(64,306)	(59,660)	(58,476)	(44,577)	(227,019)
Other Income	-	-	-	808,962	745,963	714,798	-	-	-	-	-	-	-	-	-	-
Income Tax	(912)	(912)	(2,165)	(912)	(952)	(1,936)	-	-	-	(1,936)	(1,936)	-	-	-	-	-
Net Income (Loss)	(351,390)	(614,871)	(1,426,149)	(102,826)	(928,418)	(144,613)	(464,415)	(758,802)	(317,055)	(1,411,106)	(2,949,442)	(1,311,247)	(969,681)	(2,096,761)	(1,251,170)	(5,628,861)
Stock Comp & Services Expense	52,341	473,326	547,345	733,930	915,494	919,032	108,746	382,431	258,214	210,393	959,784	149,364	308,206	714,662	288,478	1,460,710
Business Acquisition Expenses	-	128,111	-	-	162,125	-	-	-	-	-	-	-	-	-	-	-
Other Income	-	-	-	(808,962)	(742,052)	(714,798)	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	27,216	38,554	112,218	146,926	190,068	210,735	51,564	52,697	52,325	55,796	212,382	48,290	46,338	58,585	60,263	213,476
Interest Expense	-	1,416	1,001	5,302	159,538	218,927	59,122	54,640	58,528	52,818	225,108	64,306	59,660	58,476	44,577	227,019
Income Taxes	912	912	2,165	912	952	1,936	-	-	-	1,936	1,936	-	-	-	-	-
Add Bad Debt Expense	227,500	9,803	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjusted EBITDA	(43,421)	37,251	(763,419)	(24,718)	(242,293)	491,219	(244,983)	(269,034)	52,012	(1,090,163)	(1,552,168)	(1,049,287)	(555,478)	(1,261,265)	(857,852)	(3,727,656)